Molecular mechanisms regulating the hormone sensitivity of breast cancer

Eriko Tokunaga, Yuichi Hisamatsu, Kimihiro Tanaka, Nami Yamashita, Hiroshi Saeki, Eiji Oki, Hiroyuki Kitao, Yoshihiko Maehara

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Breast cancer is a heterogeneous disease. Approximately 70% of breast cancers are estrogen receptor (ER) positive. Endocrine therapy has dramatically improved the prognosis of ER-positive breast cancer; however, many tumors exhibit de novo or acquired resistance to endocrine therapy. A thorough understanding of the molecular mechanisms regulating hormone sensitivity or resistance is important to improve the efficacy of and overcome the resistance to endocrine therapy. The growth factor receptor signaling pathways, particularly the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway can mediate resistance to all forms of endocrine therapy. In contrast, FOXA1 transcription factor is a key determinant of ER function and endocrine response. Intriguingly, a link between hormone resistance induced by the PI3K/Akt/mTOR pathway and the function of FOXA1 has been suggested. In this review, we focus on the PI3K/Akt/mTOR pathway and functions of FOXA1 in terms of the molecular mechanisms regulating the hormone sensitivity of breast cancer. Endocrine therapy has dramatically improved the prognosis of ER-positive breast cancer, however, many tumors exhibit de novo or acquired resistance to endocrine therapy. A thorough understanding of the molecular mechanisms regulating hormone sensitivity or resistance is important to improve the efficacy of and overcome the resistance to endocrine therapy. In this review, we focus on the PI3K/Akt/mTOR pathway and functions of FOXA1 in terms of the molecular mechanisms regulating the hormone sensitivity of breast cancer.

Original languageEnglish
Pages (from-to)1377-1383
Number of pages7
JournalCancer Science
Volume105
Issue number11
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Phosphatidylinositol 3-Kinase
Hormones
Breast Neoplasms
Sirolimus
Estrogen Receptors
Therapeutics
Growth Factor Receptors
Neoplasms
Transcription Factors

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Tokunaga, E., Hisamatsu, Y., Tanaka, K., Yamashita, N., Saeki, H., Oki, E., ... Maehara, Y. (2014). Molecular mechanisms regulating the hormone sensitivity of breast cancer. Cancer Science, 105(11), 1377-1383. https://doi.org/10.1111/cas.12521

Molecular mechanisms regulating the hormone sensitivity of breast cancer. / Tokunaga, Eriko; Hisamatsu, Yuichi; Tanaka, Kimihiro; Yamashita, Nami; Saeki, Hiroshi; Oki, Eiji; Kitao, Hiroyuki; Maehara, Yoshihiko.

In: Cancer Science, Vol. 105, No. 11, 01.11.2014, p. 1377-1383.

Research output: Contribution to journalReview article

Tokunaga, E, Hisamatsu, Y, Tanaka, K, Yamashita, N, Saeki, H, Oki, E, Kitao, H & Maehara, Y 2014, 'Molecular mechanisms regulating the hormone sensitivity of breast cancer', Cancer Science, vol. 105, no. 11, pp. 1377-1383. https://doi.org/10.1111/cas.12521
Tokunaga E, Hisamatsu Y, Tanaka K, Yamashita N, Saeki H, Oki E et al. Molecular mechanisms regulating the hormone sensitivity of breast cancer. Cancer Science. 2014 Nov 1;105(11):1377-1383. https://doi.org/10.1111/cas.12521
Tokunaga, Eriko ; Hisamatsu, Yuichi ; Tanaka, Kimihiro ; Yamashita, Nami ; Saeki, Hiroshi ; Oki, Eiji ; Kitao, Hiroyuki ; Maehara, Yoshihiko. / Molecular mechanisms regulating the hormone sensitivity of breast cancer. In: Cancer Science. 2014 ; Vol. 105, No. 11. pp. 1377-1383.
@article{4f0483db44a34ea58f08a68c7e6bd60a,
title = "Molecular mechanisms regulating the hormone sensitivity of breast cancer",
abstract = "Breast cancer is a heterogeneous disease. Approximately 70{\%} of breast cancers are estrogen receptor (ER) positive. Endocrine therapy has dramatically improved the prognosis of ER-positive breast cancer; however, many tumors exhibit de novo or acquired resistance to endocrine therapy. A thorough understanding of the molecular mechanisms regulating hormone sensitivity or resistance is important to improve the efficacy of and overcome the resistance to endocrine therapy. The growth factor receptor signaling pathways, particularly the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway can mediate resistance to all forms of endocrine therapy. In contrast, FOXA1 transcription factor is a key determinant of ER function and endocrine response. Intriguingly, a link between hormone resistance induced by the PI3K/Akt/mTOR pathway and the function of FOXA1 has been suggested. In this review, we focus on the PI3K/Akt/mTOR pathway and functions of FOXA1 in terms of the molecular mechanisms regulating the hormone sensitivity of breast cancer. Endocrine therapy has dramatically improved the prognosis of ER-positive breast cancer, however, many tumors exhibit de novo or acquired resistance to endocrine therapy. A thorough understanding of the molecular mechanisms regulating hormone sensitivity or resistance is important to improve the efficacy of and overcome the resistance to endocrine therapy. In this review, we focus on the PI3K/Akt/mTOR pathway and functions of FOXA1 in terms of the molecular mechanisms regulating the hormone sensitivity of breast cancer.",
author = "Eriko Tokunaga and Yuichi Hisamatsu and Kimihiro Tanaka and Nami Yamashita and Hiroshi Saeki and Eiji Oki and Hiroyuki Kitao and Yoshihiko Maehara",
year = "2014",
month = "11",
day = "1",
doi = "10.1111/cas.12521",
language = "English",
volume = "105",
pages = "1377--1383",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Molecular mechanisms regulating the hormone sensitivity of breast cancer

AU - Tokunaga, Eriko

AU - Hisamatsu, Yuichi

AU - Tanaka, Kimihiro

AU - Yamashita, Nami

AU - Saeki, Hiroshi

AU - Oki, Eiji

AU - Kitao, Hiroyuki

AU - Maehara, Yoshihiko

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Breast cancer is a heterogeneous disease. Approximately 70% of breast cancers are estrogen receptor (ER) positive. Endocrine therapy has dramatically improved the prognosis of ER-positive breast cancer; however, many tumors exhibit de novo or acquired resistance to endocrine therapy. A thorough understanding of the molecular mechanisms regulating hormone sensitivity or resistance is important to improve the efficacy of and overcome the resistance to endocrine therapy. The growth factor receptor signaling pathways, particularly the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway can mediate resistance to all forms of endocrine therapy. In contrast, FOXA1 transcription factor is a key determinant of ER function and endocrine response. Intriguingly, a link between hormone resistance induced by the PI3K/Akt/mTOR pathway and the function of FOXA1 has been suggested. In this review, we focus on the PI3K/Akt/mTOR pathway and functions of FOXA1 in terms of the molecular mechanisms regulating the hormone sensitivity of breast cancer. Endocrine therapy has dramatically improved the prognosis of ER-positive breast cancer, however, many tumors exhibit de novo or acquired resistance to endocrine therapy. A thorough understanding of the molecular mechanisms regulating hormone sensitivity or resistance is important to improve the efficacy of and overcome the resistance to endocrine therapy. In this review, we focus on the PI3K/Akt/mTOR pathway and functions of FOXA1 in terms of the molecular mechanisms regulating the hormone sensitivity of breast cancer.

AB - Breast cancer is a heterogeneous disease. Approximately 70% of breast cancers are estrogen receptor (ER) positive. Endocrine therapy has dramatically improved the prognosis of ER-positive breast cancer; however, many tumors exhibit de novo or acquired resistance to endocrine therapy. A thorough understanding of the molecular mechanisms regulating hormone sensitivity or resistance is important to improve the efficacy of and overcome the resistance to endocrine therapy. The growth factor receptor signaling pathways, particularly the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway can mediate resistance to all forms of endocrine therapy. In contrast, FOXA1 transcription factor is a key determinant of ER function and endocrine response. Intriguingly, a link between hormone resistance induced by the PI3K/Akt/mTOR pathway and the function of FOXA1 has been suggested. In this review, we focus on the PI3K/Akt/mTOR pathway and functions of FOXA1 in terms of the molecular mechanisms regulating the hormone sensitivity of breast cancer. Endocrine therapy has dramatically improved the prognosis of ER-positive breast cancer, however, many tumors exhibit de novo or acquired resistance to endocrine therapy. A thorough understanding of the molecular mechanisms regulating hormone sensitivity or resistance is important to improve the efficacy of and overcome the resistance to endocrine therapy. In this review, we focus on the PI3K/Akt/mTOR pathway and functions of FOXA1 in terms of the molecular mechanisms regulating the hormone sensitivity of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84911386430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911386430&partnerID=8YFLogxK

U2 - 10.1111/cas.12521

DO - 10.1111/cas.12521

M3 - Review article

C2 - 25155268

AN - SCOPUS:84911386430

VL - 105

SP - 1377

EP - 1383

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 11

ER -